Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Kaohsiung City, Taiwan, 83301
- Novartis Investigative Site
-
Keelung, Taiwan, 20401
- Novartis Investigative Site
-
Taichung, Taiwan, 407219
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
Taipei, Taiwan, 105
- Novartis Investigative Site
-
Taoyuan, Taiwan, 33305
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged ≥ 20 years and ≤ 75 years at screening.
- Patients with written informed consent form.
- Male or female diagnosed with SLE.
Confirmed diagnosis of LN by physician. Diagnosis of LN was defined as:
- Kidney biopsy within 1 year, with histological diagnosis of LN (class III/IV/V)
- Laboratory evidence of active nephritis: spot UPCR>0.5, and/or proteinuria > 0.5 g/24 hours, and/or greater than 3+ by dipstick, and/or cellular casts.
- Patients with LN who received EC-MPS for the first time. The patients who switched from other treatment and treatment naive patients (did not receive any treatment before) could be included in this study.
- Women of childbearing potential must have used effective contraception before beginning EC MPS therapy, during therapy, and for six weeks after their last dose of EC MPS.
Exclusion Criteria:
- Previous or planned kidney transplant.
- Were receiving continuous dialysis or GFR < 30 mL/min/1.73 m2 within 3 months prior to the start of study.
- Patients with active serious digestive system disease, including infrequent cases of gastrointestinal tract ulceration with hemorrhage or perforation.
- Patients with life threatening conditions including malignancies, or severe infection in recent 6 months prior to start of study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Myfortic
Oral administration
|
There is no treatment allocation.
Patients administered Myfortic by prescription that had started before inclusion of the patient into the study were enrolled.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety profile of Enteric-coated Mycophenolate Sodium (EC-MPS) on Lupus nephritis patients
Time Frame: 12 months
|
The primary endpoint is the safety of EC-MPS in LN patients, which was assessed via the adverse events (AEs), serious adverse events (SAEs) and deaths.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reasons for study drug discontinuation
Time Frame: 12 months
|
To describe the reasons for study drug discontinuation, including poor response, loss to follow-up, etc.
|
12 months
|
|
Proportion of patients achieving renal response in estimated glomerular filtration rate (eGFR)
Time Frame: month 6, month 12
|
The proportion of patients achieving renal response in estimated glomerular filtration rate (eGFR). (eGFR within the normal range, or no less than 85% of baseline) |
month 6, month 12
|
|
Proportion of patients achieving inactive urinary sediment
Time Frame: month 6, month 12
|
The proportion of patients achieving inactive urinary sediment (no cellular casts)
|
month 6, month 12
|
|
Proportion of patients with a complete response
Time Frame: month 6, month 12
|
Patients were reported to have a complete response if their proteinuria is < 0.5 g/24 hours; or UPCR≤ 0.5.
|
month 6, month 12
|
|
Proportion of patients with a partial response
Time Frame: month 6, month 12
|
Patients were reported to have a partial response if they experience any one criteria as follows:
|
month 6, month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Glomerulonephritis
- Lupus Erythematosus, Systemic
- Nephritis
- Skin and Connective Tissue Diseases
- Lupus Nephritis
- Organic Chemicals
- Fatty Acids
- Lipids
- Acids, Acyclic
- Carboxylic Acids
- Caproates
- Mycophenolic Acid
Other Study ID Numbers
Other Study ID Numbers
- CERL080ATW12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.